Omarigliptin

Generic Name: Omarigliptin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₂₀F_₂N_₄O_₃S

CAS Number: 1226781-44-7

Unique Ingredient Identifier: CVP59Q4JE1

Background: Omarigliptin has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Chronic Renal Insufficiency.

Indication: 用于治疗2型糖尿病。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Phase 4

Not yet recruiting

Conditions: Type2diabetes

Interventions: Drug: Sulphonylureas
Drug: Alpha-Glucosidase Inhibitor
Drug: Thiazolidinediones
Drug: Omarigliptin
Drug: Other DPP4-i
Drug: SGLT2 inhibitors
Drug: Glucagon-Like Peptide-1
Drug: Receptor Agonists (GLP1RA)
Drug: Metformin

First Posted Date: 2024-06-07

Last Posted Date: 2024-07-16

Lead Sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders

Target Recruit Count: 938

Registration Number: NCT06449235

Locations: 🇧🇩
BIRDEM General Hospital, Dhaka, Bangladesh

Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Omarigliptin
Drug: Placebo
Biological: Insulin

First Posted Date: 2016-09-20

Last Posted Date: 2019-09-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 184

Registration Number: NCT02906709

A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)

Phase 3

Terminated

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Omarigliptin
Drug: Glimepiride
Drug: Glimepiride Placebo
Drug: Omarigliptin Placebo

First Posted Date: 2013-05-29

Last Posted Date: 2018-09-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 65

Registration Number: NCT01863667

Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Phase 3

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Omarigliptin
Drug: Sitagliptin
Drug: Placebo to Sitagliptin
Drug: Placebo to omarigliptin
Drug: Open-label Metformin
Drug: Open-label Glimepiride

First Posted Date: 2013-04-26

Last Posted Date: 2018-09-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 642

Registration Number: NCT01841697

A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Omarigliptin
Drug: Placebo to omarigliptin
Drug: Metformin

First Posted Date: 2013-03-20

Last Posted Date: 2018-09-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 203

Registration Number: NCT01814748

A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: MK-3102

First Posted Date: 2013-01-14

Last Posted Date: 2018-09-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 16

Registration Number: NCT01767688

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Omarigliptin
Drug: Matching placebo to omarigliptin
Drug: Matching placebo to glimepiride
Drug: Glimepiride
Drug: Insulin glargine
Drug: Metformin

First Posted Date: 2012-12-24

Last Posted Date: 2018-09-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 402

Registration Number: NCT01755156

A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo to Omarigliptin
Drug: Omarigliptin
Drug: Metformin
Drug: Placebo to metformin
Drug: Glimepiride

First Posted Date: 2012-10-30

Last Posted Date: 2018-09-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 329

Registration Number: NCT01717313

Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Matching placebo to Omarigliptin
Drug: Omarigliptin
Drug: Glimepiride
Drug: Metformin

First Posted Date: 2012-10-11

Last Posted Date: 2018-09-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 307

Registration Number: NCT01704261

Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Omarigliptin
Drug: Placebo to sitagliptin
Drug: Sitagliptin
Drug: Placebo to omarigliptin

First Posted Date: 2012-10-10

Last Posted Date: 2019-08-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 414

Registration Number: NCT01703221

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy